1. Li YJ, Dai YL, Zhang WB, Li SJ, Tu CQ: Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis. Clin Exp Med 2017, 17(1):59-69.
2. Nathenson MJ, Conley AP, Sausville E: Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 2018, 23(1):71-83.
3. Burningham Z, Hashibe M, Spector L, Schiffman JD: The epidemiology of sarcoma. Clin Sarcoma Res 2012, 2(1):14.
4. Huang R, Mao M, Lu Y, Yu Q, Liao L: A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment. Aging (Albany NY) 2020, 12(8):6966-6980.
5. He D, Wang D, Lu P, Yang N, Xue Z, Zhu X, Zhang P, Fan G: Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations. Oncogene 2021, 40(2):355-368.
6. Atianand MK, Caffrey DR, Fitzgerald KA: Immunobiology of Long Noncoding RNAs. Annu Rev Immunol 2017, 35:177-198.
7. Barreca MM, Zichittella C, Alessandro R, Conigliaro A: Hypoxia-Induced Non-Coding RNAs Controlling Cell Viability in Cancer. Int J Mol Sci 2021, 22(4).
8. Chen YG, Satpathy AT, Chang HY: Gene regulation in the immune system by long noncoding RNAs. Nat Immunol 2017, 18(9):962-972.
9. Elling R, Chan J, Fitzgerald KA: Emerging role of long noncoding RNAs as regulators of innate immune cell development and inflammatory gene expression. Eur J Immunol 2016, 46(3):504-512.
10. Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W: Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res 2019, 9(7):1354-1366.
11. Wu J, Zhang J, Shen B, Yin K, Xu J, Gao W, Zhang L: Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition. J Exp Clin Cancer Res 2015, 34:116.
12. Stratigi K, Kapsetaki M, Aivaliotis M, Town T, Flavell RA, Spilianakis CG: Spatial proximity of homologous alleles and long noncoding RNAs regulate a switch in allelic gene expression. Proc Natl Acad Sci U S A 2015, 112(13):E1577-1586.
13. Wang X, Yang J, Guo G, Feng R, Chen K, Liao Y, Zhang L, Sun L, Huang S, Chen JL: Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway. Mol Cancer 2019, 18(1):84.
14. Liu C, Tang L, Xu M, Lin Y, Shen J, Zhou L, Ho L, Lu J, Ai X: LncRNA RUSC1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-340-5p/CREB1 axis. Am J Transl Res 2021, 13(3):1022-1036.
15. Shen Y, Xu J, Pan X, Zhang Y, Weng Y, Zhou D, He S: LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth via ALDOA enhanced aerobic glycolysis. Cell Death Dis 2020, 11(4):278.
16. Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL et al: Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018, 31(2):214-234.
17. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013, 4:2612.
18. Camp RL, Dolled-Filhart M, Rimm DL: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10(21):7252-7259.
19. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015, 43(7):e47.
20. Gao J, Kwan PW, Shi D: Sparse kernel learning with LASSO and Bayesian inference algorithm. Neural Netw 2010, 23(2):257-264.
21. Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56(2):337-344.
22. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13(11):2498-2504.
23. Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, Liu X, Xu T, Sun L, Qin J et al: LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer 2019, 18(1):135.
24. Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB, Jeffers GGL, Grossman JG, Highkin MK, Tang C et al: Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun 2020, 11(1):2156.
25. Consortium ITP-CAoWG: Pan-cancer analysis of whole genomes. Nature 2020, 578(7793):82-93.
26. Yang Z, Yu L, Wang Z: PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res 2016, 28(1):65-71.
27. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464(7291):1071-1076.
28. Huang G, Yang Y, Lv M, Huang T, Zhan X, Kang W, Hou J: Novel lncRNA SFTA1P Promotes Tumor Growth by Down-Regulating miR-4766-5p via PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma. Onco Targets Ther 2020, 13:9759-9770.
29. Agarwal S, Behring M, Kim HG, Chandrashekar DS, Chakravarthi B, Gupta N, Bajpai P, Elkholy A, Al Diffalha S, Datta PK et al: TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. Mol Oncol 2020, 14(12):3007-3029.
30. Azzalin A, Moretti E, Arbustini E, Magrassi L: Cell density modulates SHC3 expression and survival of human glioblastoma cells through Fak activation. J Neurooncol 2014, 120(2):245-256.